This medical condition has either been superseded or has become inactive
| Specific Conditions |
|
| Level of Evidence | Nil (Category 4b) |
|
PRCA is a rare syndrome of severe anaemia, reticulocytopenia and a selective deficiency of erythroid progenitors. Intravenous immunoglobulin (IVIg) should be considered as first-line therapy for viral PRCA associated with parvovirus B19 in immunocompromised patients. IVIg is a reasonable option for patients with immunological PRCA who have failed other therapies (e.g. prednisone or cyclosporine). Refer to the current product information sheet for further information. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. |
|
| Bibliography |
|---|
| Anderson, D, Ali, K, Blanchette, V, et al 2007, ‘Guidelines on the use of intravenous immune globulin for hematologic conditions’, Transfusion Medicine Reviews, vol. 21, no. 2, suppl. 1, pp. S9–56. |